Evidence map›Paper›PMID 42543388›Full record

SynthesisJournal of gastroenterology2026

S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.

Abdulkareem Jomaa, Rani Bshara, Mohammed Alani, Bilind Ismail, Yousif Rajab, Dani Hayder, Halder J Abozait, Wasim Jomaa, Weys Neda, Mostafa Najim and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abdulkareem JomaaDepartment of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
Rani BsharaDepartment of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
Mohammed AlaniDepartment of Internal Medicine, Midwestern University, Arizona, USA.
Bilind IsmailDepartment of Internal Medicine, Willis-Knighton Health System, Shreveport, LA, USA.
Yousif RajabDepartment of Medicine, Pennsylvania State University, State College, PA, USA.
Dani HayderDepartment of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
Halder J AbozaitDepartment of Internal Medicine, Mount Sinai Hospital, 1500 S Fairfield Ave, Chicago, IL, 60608, USA. halder01jamal@gmail.com.ORCID http://orcid.org/0009-0003-8035-2443
Wasim JomaaDepartment of Clinical Sciences, College of Medicine, University of Zakho, Zakho Independent Administration, Zakho, Kurdistan Region, Iraq.
Weys NedaGlobal Health Departement, Uppsala University, Uppsala, Sweden.
Mostafa NajimDepartment of Medicine, Penn State Health, Hershey Medical Center, Hershey, PA, USA.
Hasan Al-ObaidiDepartment of Gastroenterology and Hepatology, University of Toledo, Toledo, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsS1P receptor modulators are emerging oral therapies for moderate-to-severe ulcerative colitis (UC); however, a comprehensive synthesis incorporating the largest number of RCTs to date, alongside Trial Sequential Analysis (TSA) and GRADE-based certainty assessment, remains lacking. We aim to evaluate the efficacy and safety of S1P receptor modulators in moderate-to-severe UC and assess the conclusiveness and certainty of the evidence.

methodsPubMed, Cochrane Library, Europe PMC, and Google Scholar were searched from inception through February 28, 2026. Eligible studies were RCTs comparing any S1P receptor modulator with placebo in adults (≥ 18 years) with UC. Pooled risk ratios (RRs) with 95% CIs were estimated using a random-effects model.

resultsA total of ten RCTs were included. During induction, S1P receptor modulators were superior to placebo for clinical remission (RR 2.77; 95% CI, 2.17-3.55; I

conclusionS1P receptor modulators demonstrated moderate-to-high certainty evidence of efficacy across all outcomes, without a significant increase in SAEs. These findings provide robust quantitative support for current guideline recommendations endorsing this oral drug class as an effective advanced therapy for moderate-to-severe UC.

Indexed as

Colitis, UlcerativeReceptors, LysosphingolipidSphingosine 1 Phosphate Receptor ModulatorsHumansOxadiazolesRandomized Controlled Trials as TopicRemission InductionSeverity of Illness IndexTreatment OutcomeOxadiazolesReceptors, LysosphingolipidSphingosine 1 Phosphate Receptor ModulatorsMeta-analysisS1P receptor modulatorsTrial Sequential AnalysisUlcerative colitis

Identifiers

PMID42543388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.